The FDA approved Viridian Therapeutics' veligrotug Lumvoa , an IGF-1R-targeted antibody for thyroid eye disease, making it the second drug in the class after Amgen's first-in-class teprotumumab Tepezza . The approval validates IGF-1R as a clinically actionable target in autoimmune disease, opens…
The US Food and Drug Administration approved Viridian Therapeutics' veligrotug Lumvoa for thyroid eye disease , making it the second IGF-1R -targeted antibody cleared for the condition and the first direct competitor to Amgen's first-in-class teprotumumab Tepezza . The decision brings to two the number of IGF-1R antibodies approved for thyroid eye disease and hands Viridian a product positioned for a market that Amgen has had to itself.
Thyroid eye disease is an autoimmune condition of the orbit, the bony cavity that holds the eye. The immune system turns against the tissue behind the globe: orbital fibroblasts become activated, expand, secrete matrix, and draw in inflammatory cells. Patients develop protruding eyes, eyelid retraction, double vision, and pain around the eye, and in severe cases the optic nerve can be compressed. Medical options before this drug class included corticosteroids, orbital radiotherapy, and surgical decompression, approaches that manage inflammation and anatomy rather than the receptor signaling that drives tissue expansion.
The second approval matters for three reasons. It validates IGF-1R as a clinically actionable target in autoimmune disease, a position that previously rested on a single drug. It creates the first commercial competition within the class. And it arrives with an unresolved question attached: veligrotug may compete by offering a convenience advantage over teprotumumab, but the basis of that advantage has not been specified.
The core facts of the decision are straightforward. The FDA approved veligrotug, marketed as Lumvoa, for the treatment of thyroid eye disease, and Viridian Therapeutics is the license holder. The drug is an antibody directed at the type 1 insulin-like growth factor receptor, and it is the second such antibody to reach the US market for this indication. The first, Amgen's teprotumumab Tepezza , is the first-in-class anti-IGF-1R antibody for the disease.
The record is thinner beyond that point. It specifies what was approved, by whom, and for what disease, but it does not specify the dosing regimen, the route of administration, the efficacy measures on which the approval was based, or the safety profile that distinguishes veligrotug from teprotumumab. It also does not specify the basis of the convenience claim. Those are not incidental gaps. For a second entrant in a therapeutic class, the clinically decisive facts are the ones that describe how the new drug differs from the established one, and those facts are absent here.
The approval is documented in the 2026 scientific literature, volume 25, page 583, under DOI 10.1038/d41573-026-00118-1. The citation records the approval, the class, and the competitive framing, and it flags the convenience question explicitly. It carries the same limits as the rest of the record: a convenience advantage is asserted without explanation, and no comparative data are presented. What the record establishes, therefore, is the existence of a second approved drug, not yet its place relative to the first. Approval settles what a drug is; evidence settles what it is worth. The current record settles the first for veligrotug and leaves the second open.
The acting authority is the US Food and Drug Administration , and the action is an approval of a biological product. For a monoclonal antibody, that means the FDA accepted a Biologics License Application and determined that the product met the applicable statutory standard for approval. The scope of the approval is the treatment of thyroid eye disease, and the license authorizes Viridian to market veligrotug in the United States for that indication.
An approval of this kind binds the license holder in specific ways. Viridian must manufacture the product consistently with the chemistry, manufacturing, and controls commitments in the application; it must report adverse events; and it must comply with any postmarketing requirements or commitments the agency attached to the approval. The approved label defines what the company may claim. Promotional statements must be consistent with that label, which matters directly for the convenience question: if the advantage is not reflected in the approved labeling, Viridian cannot promote it, and if it is reflected, the claim has passed through FDA review.
The label is the operational document of the decision. It carries the indication, the dosing information, the contraindications, and the warnings, and it is the text against which both promotion and prescribing are checked. For that reason the label, not the approval announcement, is where the practical differences between veligrotug and teprotumumab will first become visible.
The approval binds Amgen commercially, not legally. Amgen's position changes because its product now has a competitor in the class, not because the FDA ordered any change to Tepezza. The approval also does not bind clinicians, who remain free to prescribe either drug, or payers, who will make their own coverage decisions. And it is a US decision; it confers no marketing right outside the United States, although regulators elsewhere will weigh it as evidence.
The biology starts with the target. IGF-1 , insulin-like growth factor 1, is a peptide hormone of about 70 amino acids, structurally related to insulin. Its receptor, IGF-1R , is a transmembrane receptor tyrosine kinase. When the ligand binds, the receptor phosphorylates intracellular substrates and activates signaling cascades, notably the PI3K-AKT and RAS-MAPK pathways, that drive cell survival, proliferation, and matrix production. Neither approved drug is a peptide; both are full-size monoclonal antibodies . But the receptor they block is part of a peptide-hormone signaling system, which is the direct point of contact between this approval and peptide science.
The disease context explains why that receptor sits at the center of the orbit. Thyroid eye disease arises in the setting of Graves' disease, an autoimmune condition in which autoantibodies activate the TSH receptor TSHR on thyroid cells. The same receptor is expressed on orbital fibroblasts, along with IGF-1R, and the two receptors cooperate. In orbital tissue, TSHR and IGF-1R can associate at the cell surface, and IGF-1R kinase activity amplifies the cellular response to TSH-receptor activation. The cells that bear both receptors are not passive targets: orbital fibroblasts and preadipocytes from patients overexpress IGF-1R, and when stimulated they proliferate, differentiate into adipocytes, and secrete hyaluronan , a hydrophilic glycosaminoglycan that binds water and swells the tissue. Inflammatory cells follow, and the expanding tissue, confined by the bony orbit, pushes the eye forward, retracts the eyelids, restricts the extraocular muscles, and in severe cases compresses the optic nerve. Blocking IGF-1R interrupts this program at an early point.
An anti-IGF-1R antibody works by occupying the receptor's extracellular domain, blocking access of IGF-1 and related ligands, and driving the receptor off the cell surface through internalization. The result is a reduction in the signaling that fuels fibroblast activation, adipogenesis, and hyaluronan secretion. Because IGF-1R is closely related to the insulin receptor and can pair with it to form hybrid receptors, the class carries metabolic considerations, chiefly for glucose handling, and any second entrant's safety profile has to be read against that backdrop.
Receptor blockade does not remove the autoantibodies that initiate the disease, and it does not directly suppress the TSH receptor. The therapeutic logic is instead to sever an amplification loop: even if the initiating autoantibodies remain present, the tissue cannot mount the full pathogenic response if the co-receptor that amplifies it is silenced. The approval of veligrotug does not change that logic. It changes the number of tools available to act on it, and it supplies a second, independent test of the proposition that a peptide-hormone receptor expressed in autoimmune tissue can be a durable drug target.
The convenience claim is the one competitive assertion in the approval record, and it hangs without support. Veligrotug may compete by offering a convenience advantage over teprotumumab, but the basis of the advantage is not stated. For a second entrant, that is the difference between a marketing position and a clinical one.
In antibody therapy for a chronic autoimmune disease, convenience is usually a function of a small set of variables: whether the drug is given intravenously or subcutaneously; how long each administration takes; how often doses are given; how long the full course lasts; whether premedication is required; and what monitoring is attached. Any of these could underlie the claim for veligrotug, and none of them is established in the public record. The precise assertion is narrow: not that veligrotug is more convenient, but that it may compete on that basis. In a disease course that spans months of repeated administration, small differences in how a drug is given accumulate into differences in patient burden and clinic capacity.
The distinction matters to the clinicians who will prescribe the drug and the payers who will cover it. An unspecified convenience advantage cannot be weighed against known deficits, and no comparative efficacy or safety data have been presented to offset it. What would settle the question is the approved labeling, which fixes the dose, route, frequency, and duration of therapy, and head-to-head or well-matched indirect comparisons of outcomes. Until those documents are available, the convenience claim remains an assertion in search of evidence.
Clinicians now have two approved antibodies for thyroid eye disease, and the choice between them is not yet evidence-based in any public sense. The two products share a target and an indication but are distinct biologics with distinct manufacturing, dosing, and safety profiles, and the comparative information that would guide a first-line choice has not been released. What the second approval does supply is negotiating room: a second product in a class changes the conversation about access, coverage, and price, even before comparative data exist.
For researchers, the approval converts IGF-1R from a target validated by a single drug into one validated by two independent development programs. That strengthens the case for studying the receptor beyond the antibody format. Several questions now have sharper commercial and scientific point: why some patients respond and others do not; whether receptor density in orbital tissue predicts outcome; how much of the clinical effect depends on blocking the ligand, on downregulating the receptor, or on disrupting the TSHR-IGF-1R complex; and whether the class effect can be reproduced with smaller molecules, peptide-based modulators, or agents that spare the insulin receptor family.
For the supply chain, the second approval means two independent manufacturing and distribution systems for antibodies against the same target. Both veligrotug and teprotumumab are full-length IgG molecules whose production depends on mammalian cell culture, defined upstream and downstream processes, and validated analytical methods. A second approved product doubles the capacity commitments for the target and introduces a second set of reliability, quality, and continuity questions for the hospitals and infusion centers that administer the drugs. It also introduces the possibility, ordinary in markets with two suppliers, of price competition and coverage…
Peptides referenced: IGF-1.
Related reading: Bachem Holding AG Focuses on Peptide Manufacturing Amid Growing Biotech Demand, GLP-1 Drug Use Among US Adults Reaches 11%, Gallup Poll Shows, Dr. Reddy's Halts Generic Semaglutide Supply Over API Issue, Dr. Reddy's Expects Semaglutide Shortage Through Late October.